Author

Andrea Mancini

h-index 0 View on Semantic Scholar

We have 3 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Deubiquitinase-targeting chimeras (DUBTACs): a game-changing approach for targeted protein stabilization in drug discovery.

Targeted protein degradation (TPD) has transformed drug discovery by enabling event-driven elimination of pathogenic proteins, but many diseases arise from protein insufficiency and require restoration rather than removal. Deubiquitinase (DUB)-targeting chimeras (DUBTACs) offer a complementary proximity-pharmacology ap...

G. Hailu, Emanuele Fabbrizi, Andrea Mancini et al. · Drug Discovery Today · 0 citations

Review Open access Jul 2026

METTL1/WDR4 Complex: A Novel Epitranscriptomic Target at the Crossroads of RNA Methylation and Drug Discovery

Advances provide the first chemical foothold for therapeutic modulation of m7G pathways and underscore METTL1 as a promising yet complex target requiring careful biological stratification.

Emanuele Fabbrizi, Gebremedhin S. Hailu, Andrea Mancini et al. · Journal of Medicinal Chemist... · 0 citations

Open access Aug 2026

Molecular Striptease of a Thiadiazolopyrimidine Hit Yields a Streamlined, Artifact-Free NADPH Mimic for NOX Inhibition

Compound 5, although aqueous solubility issues limited its cellular antiproliferative performance, represents a specific, artifact-free architectural starting point for future selective NOX inhibitor development.

Emanuele Fabbrizi, Andrea Mancini, Chiara Lambona et al. · ACS Medicinal Chemistry Lett... · 0 citations